Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Kupfer

Showing results (21-30 of 99) with videos related to

Pageof 10
Sort By:
The American Journal of Medicine|September 4, 2012
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomilGeorge L Bakris, Domenic Sica, William B White, et al.
Hypertension (Dallas, Tex. : 1979)|June 20, 2012
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertensionWilliam C Cushman, George L Bakris, William B White, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|April 27, 2012
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial studyDomenic Sica, George L Bakris, William B White, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 29, 2023
Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trialJeremy M Shefner, Bill Jacobsen, Stuart Kupfer, et al.
Thrombosis and Haemostasis|October 2, 2010
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgeryJeffrey I Weitz, Charlie Cao, Bengt I Eriksson, et al.
Clinical Pharmacokinetics|February 5, 2025
Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of AficamtenDonghong Xu, Justin D Lutz, Punag Divanji, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 8, 2024
Plasma neurofilament analysis in VITALITY-ALSTyrell J Simkins, Stuart Kupfer, Fady I Malik, et al.
Clinical and Translational Science|April 9, 2025
Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy ParticipantsNeha Maharao, Donghong Xu, Tyrell J Simkins, et al.
The American Journal of Cardiology|September 26, 2006
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST])Rhonda Cooper-Dehoff, Jerome D Cohen, George L Bakris, et al.
Journal of Neuromuscular Diseases|May 5, 2025
Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALSTyrell Simkins Lead, Jeremy M Shefner, Stuart Kupfer, et al.
Pageof 10

Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
The American Journal of Medicine|September 4, 2012
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomilGeorge L Bakris, Domenic Sica, William B White, et al.
Hypertension (Dallas, Tex. : 1979)|June 20, 2012
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertensionWilliam C Cushman, George L Bakris, William B White, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|April 27, 2012
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial studyDomenic Sica, George L Bakris, William B White, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 29, 2023
Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trialJeremy M Shefner, Bill Jacobsen, Stuart Kupfer, et al.
Thrombosis and Haemostasis|October 2, 2010
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgeryJeffrey I Weitz, Charlie Cao, Bengt I Eriksson, et al.
Clinical Pharmacokinetics|February 5, 2025
Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of AficamtenDonghong Xu, Justin D Lutz, Punag Divanji, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 8, 2024
Plasma neurofilament analysis in VITALITY-ALSTyrell J Simkins, Stuart Kupfer, Fady I Malik, et al.
Clinical and Translational Science|April 9, 2025
Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy ParticipantsNeha Maharao, Donghong Xu, Tyrell J Simkins, et al.
The American Journal of Cardiology|September 26, 2006
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST])Rhonda Cooper-Dehoff, Jerome D Cohen, George L Bakris, et al.
Journal of Neuromuscular Diseases|May 5, 2025
Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALSTyrell Simkins Lead, Jeremy M Shefner, Stuart Kupfer, et al.
Pageof 10